Document Detail

Neuropathologic substrate of mild cognitive impairment.
MedLine Citation:
PMID:  16401735     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To define the neuropathologic findings in amnestic mild cognitive impairment (MCI) and early Alzheimer disease (EAD). METHODS: The mean numbers of diffuse plaques, neuritic plaques (NPs), and neurofibrillary tangles (NFTs) in 4 neocortical regions and 4 ventromedial temporal lobe regions were counted in 10 patients with amnestic MCI and compared with the mean numbers in 23 normal control subjects and 10 patients with EAD, and then were compared with memory performance. All of the controls and patients were followed longitudinally. RESULTS: Patients with MCI showed no significant difference (P>.05) in the number of diffuse plaques from that in normal controls or patients with EAD. In patients with MCI, the number of NPs was significantly elevated in all 4 neocortical regions and amygdala compared with controls (P<.01 to <.001). There were no significant differences (P>.05) in the number of NPs between MCI and EAD cerebral cortex, but significant increases were present for NPs in EAD amygdala and subiculum compared with MCI (P<.01). In patients with MCI compared with controls, the only significant increase in NFTs in the neocortex was in the parietal lobe. However, the number of NFTs was significantly elevated in MCI in all 4 ventromedial temporal lobe structures compared with controls (P<.01 to <.001). In comparing MCI with EAD, there were significant increases in NFTs in EAD in frontal and temporal lobes, amygdala, and subiculum (P<.01). The numbers of NPs and NFTs were significantly elevated in all of the neocortical regions and ventromedial temporal lobe regions in patients with EAD compared with controls (P<.001). Memory function was significantly correlated with NFTs in CA1 of the hippocampus (P<.01) and the entorhinal cortex (P<.05). CONCLUSIONS: In patients with amnestic MCI who were followed longitudinally, the early changes of Alzheimer disease were present. The NFTs were slightly more prominent than beta-amyloid peptide deposition in the progression from normal to MCI to EAD. Ventromedial temporal lobe NFTs probably represent the substrate for memory decline in MCI. From a neuropathologic perspective, it appears that amnestic MCI is, in reality, EAD.
William R Markesbery; Frederick A Schmitt; Richard J Kryscio; Daron G Davis; Charles D Smith; David R Wekstein
Related Documents :
12609165 - Proposal for a new five-axis classification scheme for psychoses of epilepsy.
10636075 - Fistula in ano: evaluation with low-field magnetic resonance imaging (0.1 t).
6941925 - Genetic markers in epilepsy: a survey.
17448635 - Lack of differences of motorcortical excitability in the morning as compared to the eve...
21427295 - Prolonged neuromuscular paralysis following rapid-sequence intubation with succinylchol...
3810425 - Primary hyperparathyroidism in northern sweden.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Archives of neurology     Volume:  63     ISSN:  0003-9942     ISO Abbreviation:  Arch. Neurol.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-01-10     Completed Date:  2006-03-02     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0372436     Medline TA:  Arch Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  38-46     Citation Subset:  AIM; IM    
Alzheimer's Disease Center, University of Kentucky, Lexington, KY 40536-0230, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Alzheimer Disease / complications,  pathology*
Cognition Disorders / etiology,  pathology*
Memory / physiology
Neocortex / pathology
Neurofibrillary Tangles / pathology*
Neuropsychological Tests / statistics & numerical data
Senile Plaques / pathology*
Temporal Lobe / pathology
Grant Support
5-P50-AG05144/AG/NIA NIH HHS
Comment In:
Arch Neurol. 2006 Jan;63(1):15-6   [PMID:  16401731 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implication...
Next Document:  A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.